TrialJournal of neurology, neurosurgery, and psychiatry2015

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Stephen D Silberstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.